HCA shares fell 3.3% after earnings, with investors likely focused on management’s preliminary view that 2027 earnings will be generally consistent with 2026—not a return to growth—amid persistent payer-mix pressure and $550 million to $650 million less in Medicaid supplemental payment net benefits. Third-quarter volumes improved, but exchange-related shifts to uninsured patients weighed on EBITDA.
HCA Healthcare’s stock rose modestly by 1.5% as volume growth and Medicaid supplemental payments partly offset financial pressure from a significant payer mix shift driven by a surge in uninsured patients after the expiration of enhanced premium tax credits.
HCA Healthcare delivered robust third-quarter results with a 42% increase in adjusted diluted earnings per share and a 9.6% revenue growth, driven by volume expansion and improved payer mix.